IKKα通过不同机制介导生长促进和生长抑制信号诱导的c-Fos表达和AP-1活化

目的:探讨IKK激酶催化亚基IKKα在分别介导生长促进信号(血清)和生长抑制信号(紫外线UVB)诱导的反应中,调控转录因子AP-1关键组成亚基c-Fos实现诱导表达的信号传递机制。方法:分别采用Western印迹、RT-PCR和萤光素酶报道分析系统检测血清和紫外线刺激反应状态下IKKα对c-Fos诱导表达和AP-1诱导活化的调控作用;通过转染I-κBα功能抑制型突变体I-κBα-AA,观察NF-κB诱导活化受抑时,c-Fos诱导表达和AP-1诱导活化水平的改变情况。结果:IKKα在生长促进和生长抑制信号诱导的反应中,都能够实现对转录因子AP-1及其关键组成亚基c-Fos诱导表达的调控作用。其中,在血清反应中IKKα可通过NF-κB依赖方式在转录水平调控c-Fos的诱导表达,而在UVB反应中IKKα通过转录非依赖方式调控c-Fos的诱导表达。结论:IKKα能分别以NF-κB依赖和非依赖方式参与调控生长促进和生长抑制信号诱导的反应。     

阻断泛素-蛋白酶体通路对人原代白血病细胞的作用

阻断泛素-蛋白酶体通路对不同类型细胞具有完全不同的结果, 但未见对原代白血病细胞作用的报道. 观察了阻断上述通路对8例白血病患者和10例正常人骨髓单个核细胞(MNC)的作用. 结果表明, 不同个体原代白血病细胞对阻断此通路的反应敏感性存在明显差异, 其中3例细胞极为敏感, 24 h以内90%细胞被迅速诱发凋亡, 而正常人骨髓MNC对阻断泛素蛋白酶体通路反应不敏感, 未观察到凋亡现象发生. 进一步的免疫印迹实验发现, 对上述通路敏感的原代白血病细胞Bcl-2蛋白表达量较高, 而且在凋亡过程中发生了特异位点的酶解;对上述通路不敏感的细胞(包括正常人骨髓MNC)Bcl-2蛋白低表达, 或Bcl-2高表达但未能检测到其特异性酶解现象. 结合其他实验结果, 提示细胞中Bcl-2蛋白是否发生特异位点酶解与细胞对阻断上述通路的敏感性之间具有相关性, 为进一步研究不同种类细胞对阻断泛素-蛋白酶体通路敏感性差异的机制提供了线索.     

两个新的红细胞分化相关因子的cDNA克隆及功能探讨

曾报道在终末分化阶段的红细胞中可表达一些与珠蛋白基因增强子HS2序列特异结合的蛋白因子, 并利用杂交瘤技术制备了两株针对上述蛋白的单克隆抗体. 为获得编码这些因子的基因, 实验利用这两株单抗筛选构建于l gt11的人胚肝cDNA表达文库, 并获得阳性克隆. 经分析, 其中一株 cDNA克隆具有全长编码序列(EDRF1), 另一株为具有可读框的cDNA片段(EDRF2), 由它编码的氨基酸序列含有反式调节因子特有的亮氨酸拉链结构域. 与GenBank作同源比较后确定上述两株cDNA序列均未见报道. Northern印迹结果表明, 它们编码的蛋白质为红细胞分化相关蛋白. RT-PCR系统地观察了EDRF1, EDRF2在多种细胞株和组织中的表达, 提供了重要的功能线索. EDRF1和EDRF2主要在造血系统和早期的胚胎多种组织表达, 说明它与血细胞成熟和早期的组织发育相关, 也可能是传递早期造血与胚胎发育的分子语言.     

Effects of inhibition of ubiquitin-proteasome pathway on human primary leukemic cells

Though there were a lot of reports about the totally different responses to the inhibition of ubiquitin-proteasome pathway in different kinds of cell lines, much less has been known about the responses in primary human leukemic cells. In this study, the effects of inhibition of ubiq-uitin-proteasome pathway on human bone marrow (BM) mononuclear cells (MNCs) obtained from 10 normal persons and 8 leukemia patients were examined. The results showed that the responses obviously varied individually. Among them, BM MNCs in 3 cases of leukemic patients were extremely sensitive, demonstrated by that > 90% cells were induced to undergo apoptosis within 24 h, but MNCs in 10 cases of normal persons showed resistance to the inhibition and no apoptosis was observed. Furthermore, Western blots revealed that the Bcl-2 expression was relatively high in the sensitive primary leukemia cells, and especially the cleavage of 26 ku Bcl-2 into a 22 ku fragment occurred during the induction of apoptosis. In contrast, the Bcl-2 expression was either undetectable or detectable but no cleavage of that above was observed in the cells insensitive to the inhibition of the pathway (including BM MNCs in normal persons). Together with the observations on the leukemic cell lines, these findings suggested the correlation of the specific cleavage of Bcl-2 into a shortened fragment with the sensitivity of cells to the inhibition of ubiquitin-proteasome pathway, which provides clues to the further understanding of the mechanisms of that dramatically different responses existing in different kinds of cells to the inhibition of ubiq-uitin-proteasome pathway.     

多药抗药基因Mdrl探针的克隆及初步应用

多药抗药基因Mdrl的表达水平与细胞的耐药性直接相关,检测Mdrl的表达水平可预测化疗的效果以及预后,用分子原位杂交的方法可检测单个细胞中Mdrl的表达水平.用PCR扩增方法获得了一段特异的DNA片段,并将其克隆到pUC18载体中,经DNA序列分析证明与文献报道一致,此探针可用于临床标本的分子杂交检测.     

HER-2/neu胞外配体结合区2在大肠杆菌中可溶性表达及纯化

用PCR技术扩增HER 2 neu胞外配体结合区 2 (RLD2 )cDNA ,并将扩增的基因片段克隆于硫氧还蛋白 (TrxA)原核表达载体中 ,获得TrxA RLD2融合蛋白的可溶性表达 .通过插入偶联翻译序列 ,实现TrxA与RLD2蛋白在大肠杆菌中的共表达 .表达产物经免疫印记检测可被抗HER 2 neu特异性抗体识别 .经离子交换层析和钴亲和层析纯化 ,RLD2蛋白的纯度达 90 % .用质谱法分析RLD2蛋白的分子量 ,与预期值相符 .结果表明 ,利用TrxA表达体系在大肠杆菌中获得了HER 2 neuRLD2蛋白高效可溶性表达     

用一个简单快速的RT-PCR技术筛选白细胞介素-6作用相关基因

为了研究白细胞介素-6(IL-6)作用相关基因以及一些可能受IL-6调控的基因,利用一个简单快速的以PCR为基础的方案,检测了IL-6处理和未处理的Sko007细胞中基因表达的差异,克隆并鉴定了差异表达基因的cDNA片段.首先用6-mer寡核苷酸引物进行反转录从而最大限度地将mRNA编码区序列生成cDNA;然后用2或3个较长的随机引物进行PCR扩增,并以不同引物组合重复PCR增扩;扩增产物在2%琼脂糖凝胶上电泳分离,回收差异片段并直接用于克隆、测序及进一步分析.在此研究中,获得了3个表达序列标签(EST),其中一个为新的基因片段,反向RNA杂交有力证实了它们与IL-6作用的相关性.进一步的生物信息学分析表明,新基因片段STRF17在多种组织中表达.     

CTLA4Ig融合蛋白在CHO细胞中的表达

CTLA4Ig是人CTLA4胞外区与人免疫球蛋白铰链区、CH2区、CH3区组成的融合蛋白,可以与B7结合,通过阻断B7与CD28的结合,从而阻断B7介导的T细胞活化必需的共刺激信号,可作为免疫抑制剂用于器官移植。将CTLA4Ig融合分子克隆到真核表达载体pCI-dhfr,并用脂质体方法转染到COS7和CHO-dhfr-细胞中,用氨甲喋呤筛选转染的CHO-dhfr-细胞。用RT-PCR、ELISA、细胞免疫荧光染色和Western-blot鉴定重组蛋白的表达。采用A蛋白纯化重组蛋白。     

人FKBP12的基因克隆及其表达产物的生物活性

为获得具有生物学活性的 h FKBP1 2 ,筛选新型的促神经再生药物 .采用 RT- PCR、计算机辅助 p BV2 2 0中外源基因高效表达的数学模型预测方法及超滤截留纯化方法 ,从人 T淋巴白血病细胞系 Jurkat中成功扩增出 h FKBP1 2基因 .按照外源基因高效表达的数学模型 ,将其进行优化改构后 ,在 p BV2 2 0中实现了高效表达 ,表达量约 2 0 % .重组的包涵体蛋白经复性 ,纯化至电泳纯 ,纯化后的 h FKBP1 2显示出肽基脯氨基顺反异构酶活性 .表明原核表达的 h FKBP1 2具有其天然生物学活性     

Effects of inhibition of ubiquitin-proteasome pathway on human primary leukemic cells

Though there were a lot of reports about the totally different responses to the inhibition of ubiquitin-proteasome pathway in different kinds of cell lines, much less has been known about the responses in primary human leukemic cells. In this study, the effects of inhibition of ubiquitin-proteasome pathway on human bone marrow (BM) mononuclear cells (MNCs) obtained from 10 normal persons and 8 leukemia patients were examined. The results showed that the responses obviously varied individually. Among them, BM MNCs in 3 cases of leukemic patients were extremely sensitive, demonstrated by that >90% cells were induced to undergo apoptosis within 24 h, but MNCs in 10 cases of normal persons showed resistance to the inhibition and no apoptosis was observed. Furthermore, Western blots revealed that the Bcl-2 expression was relatively high in the sensitive primary leukemia cells, and especially the cleavage of 26 ku Bcl-2 into a 22 ku fragment occurred during the induction of apoptosis. In contrast, the Bcl-2 e